Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with 
ovarian serous cystadenocarcinoma treated with chemotherapy

Cong,Lan‑Xiang; Zhai,Xiang‑Hong; Wu,Feng‑Xia; Zhu,Dong‑Yi; Wang,An‑Cong

doi:10.3892/ol.2016.4223

Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy

Authors:
- Lan‑Xiang Cong
- Xiang‑Hong Zhai
- Feng‑Xia Wu
- Dong‑Yi Zhu
- An‑Cong Wang
View Affiliations

Affiliations: Department of Reproductive Medicine, Linyi People's Hospital, Linyi, Shandong 276003, P.R. China, Department of Obstetrics and Gynecology, Linyi Health School, Linyi, Shandong 276000, P.R. China, Department of Anatomy, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: February 11, 2016 https://doi.org/10.3892/ol.2016.4223
Pages: 2525-2531

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The effects of platinum-based drugs are controlled by genes that are involved in DNA detoxification, including glutathione S‑transferase (GST)P1 and GSTM1, which have been associated with increased benefits in the chemotherapeutic treatment of patients with ovarian cancer. The present study assessed the effect of single nucleotide polymorphisms in GST genes on the overall survival (OS) of patients with ovarian serous cystadenocarcinoma that were treated with chemotherapy. A total of 95 patients received treatment with a carboplatin‑based or alternative chemotherapy. Polymorphisms in the patients were genotyped using the following methods: Pyrosequencing, to identify GSTP1 Ile105Val; a relative quantification method, to identify the copy number variation in GSTM1; and polymerase chain reaction followed by gel electrophoresis, to identify the null vs. non‑null genotypes of GSTM1. The association between genotypes and OS of patients was assessed using Kaplan‑Meier survival curves and Cox proportional hazards regression analysis. The OS of patients treated with paclitaxel + carboplatin‑based chemotherapy was significantly increased, compared with patients treated with alternative forms of chemotherapy (P=0.035). The OS of patients did not differ significantly between different GSTP1 genotypes (log‑rank test, P=0.17). Cox proportional hazards regression analysis revealed that, since the start of the treatment, there was not a significant association between the GSTP1 isoleucine allele and the OS for heterozygous carriers of the isoleucine allele [hazards ratio (HR), 1.78; 95% confidence interval (CI), 0.77‑4.12; P=0.18] and no homozygous carriers of the valine allele had been detected (HR, 0.00). There was no significant difference between GSTM1 genotypes, according to Kaplan‑Meier survival analysis (log‑rank test, P=0.83). Patients that possessed ≤1 copy of GSTM1 exhibited no decrease in OS (HR, 0.96; 95% CI, 0.37‑2.51; P=0.94), compared with patients that possessed two copies of GSTM1 (HR, 0.71; 95% CI, 0.22‑2.28; P=0.56). Overall, the present results suggest that there are no associations between polymorphisms in the GSTP1 and GSTM1 genes and the OS of patients with ovarian cancer following administration of adjuvant chemotherapy.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar : PubMed/NCBI
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
3	Partridge EE and Barnes MN: Epithelial ovarian cancer: Prevention, diagnosis, and treatment. CA Cancer J Clin. 49:297–320. 1999. View Article : Google Scholar : PubMed/NCBI
4	Harries M and Gore M: Part. I Chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 3:529–536. 2002. View Article : Google Scholar : PubMed/NCBI
5	Petrelli F, Zaniboni A, Coinu A, Cabiddu M, Ghilardi M, Sgroi G and Barni S: Cisplatin or not in advanced gastric cancer: A systematic review and meta-analysis. PLoS One. 8:e830222013. View Article : Google Scholar : PubMed/NCBI
6	Tan S, Peng X, Peng W, Zhao Y and Wei Y: Enhancement of oxaliplatin-induced cell apoptosis and tumor suppression by 3-methyladenine in colon cancer. Oncol Lett. 9:2056–2062. 2015.PubMed/NCBI
7	Kweekel DM, Gelderblom H and Guchelaar HJ: Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev. 31:90–105. 2005. View Article : Google Scholar : PubMed/NCBI
8	Jun L, Haiping Z and Beibei Y: Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients. Swiss Med Wkly. 139:724–728. 2009.PubMed/NCBI
9	Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Lee JH, Kim HN, Shin MH, Kweon SS, Lee JH, et al: BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. Cancer Sci. 101:1247–1254. 2010. View Article : Google Scholar : PubMed/NCBI
10	Yan H, Jia H, Gao H, Guo X and Xu B: Identification, genomic organization, and oxidative stress response of a sigma class glutathione S-transferase gene (AccGSTS1) in the honey bee, Apis cerana cerana. Cell Stress Chaperones. 18:415–426. 2013. View Article : Google Scholar : PubMed/NCBI
11	Vontas JG, Small GJ and Hemingway J: Glutathione S-transferases as antioxidant defence agents confer pyrethroid resistance in Nilaparvata lugens. Biochem J. 357:65–72. 2001. View Article : Google Scholar : PubMed/NCBI
12	Hayes JD and Pulford DJ: The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 30:445–600. 1995. View Article : Google Scholar : PubMed/NCBI
13	Chan EC, Lam SY, Fu KH and Kwong YL: Polymorphisms of the GSTM1, GSTP1, MPO, XRCC1 and NQO1 genes in Chinese patients with non-small cell lung cancers: Relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genet Cytogenet. 162:10–20. 2005. View Article : Google Scholar : PubMed/NCBI
14	Ye F, Liu Z, Tan A, Liao M, Mo Z and Yang X: XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: A meta-analysis. Cancer Chemother Pharmacol. 71:733–740. 2013. View Article : Google Scholar : PubMed/NCBI
15	Economopoulos KP and Sergentanis TN: GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: A comprehensive meta-analysis. Eur J Cancer. 46:1617–1631. 2010. View Article : Google Scholar : PubMed/NCBI
16	Funke S, Timofeeva M, Risch A, Hoffmeister M, Stegmaier C, Seiler CM, Brenner H and Chang-Claude J: Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics. 11:33–41. 2010. View Article : Google Scholar : PubMed/NCBI
17	Zaanan A, Dalban C, Emile JF, Blons H, Fléjou JF, Goumard C, Istanbullu M, Calmel C, Alhazmi K, Validire P, et al: ERCC1, XRCC1 and GSTP1 single nucleotide polymorphisms and survival of patients with colon cancer receiving oxaliplatin-based adjuvant chemotherapy. J Cancer. 5:425–432. 2014. View Article : Google Scholar : PubMed/NCBI
18	Marsh S, King CR, Garsa AA and McLeod HL: Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol. 311:97–114. 2005.PubMed/NCBI
19	Butkiewicz D, Rusin M, Sikora B, Lach A and Chorąży M: An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer. Mol Biol Rep. 38:5231–5241. 2011. View Article : Google Scholar : PubMed/NCBI
20	Kizys MM, Cardoso MG, Lindsey SC, Harada MY, Soares FA, Melo MC, Montoya MZ, Kasamatsu TS, Kunii IS, Giannocco G, et al: Optimizing nucleic acid extraction from thyroid fine-needle aspiration cells in stained slides, formalin-fixed/paraffin-embedded tissues, and long-term stored blood samples. Arq Bras Endocrinol Metabol. 56:618–626. 2012. View Article : Google Scholar : PubMed/NCBI
21	Chai H, Pan J, Zhang X, Zhang X, Shen X, Li H, Zhang K, Yang C, Sheng H and Gao H: ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese. Int J Clin Exp Med. 5:186–194. 2012.PubMed/NCBI
22	Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS and Wang WS: Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci. 101:530–535. 2010. View Article : Google Scholar : PubMed/NCBI
23	Lv H, Li Q, Qiu W, Xiang J, Wei H, Liang H, Sui A and Liang J: Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer. Pathol Oncol Res. 18:1009–1014. 2012. View Article : Google Scholar : PubMed/NCBI
24	Ali-Osman F, Akande O, Antoun G, Mao JX and Buolamwini J: Molecular cloning, characterization and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem. 272:10004–10012. 1997. View Article : Google Scholar : PubMed/NCBI
25	Godschalk RW, Dallinga JW, Wikman H, Risch A, Kleinjans JC, Bartsch H and Van Schooten FJ: Modulation of DNA and protein adducts in smokers by genetic polymorphisms in GSTM1, GSTT1, NAT1 and NAT2. Pharmacogenetics. 11:389–398. 2001. View Article : Google Scholar : PubMed/NCBI
26	Gertig DM, Stampfer M, Haiman C, Hennekens CH, Kelsey K and Hunter DJ: Glutathione S-transferase GSTM1 and GSTT1 polymorphisms and colorectal cancer risk: A prospective study. Cancer Epidemiol Biomarkers Prev. 7:1001–1005. 1998.PubMed/NCBI
27	Slattery ML, Potter JD, Samowitz W, Bigler J, Caan B and Leppert M: NAT2, GSTM-1, cigarette smoking, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev. 7:1079–1084. 1998.PubMed/NCBI
28	Li QF, Yao RY, Liu KW, Lv HY, Jiang T and Liang J: Genetic polymorphism of GSTP1: Prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean Med Sci. 25:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
29	Hong J, Han SW, Ham HS and Kim TY, Choi IS, Kim BS, Oh DY, Im SA, Kang GH, Bang YJ and Kim TY: Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol. 67:1323–1331. 2011. View Article : Google Scholar : PubMed/NCBI
30	Watson MA, Stewart RK, Smith GB, Massey TE and Bell DA: Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 19:275–280. 1998. View Article : Google Scholar : PubMed/NCBI
31	Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC and Lenz HJ: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst. 94:936–942. 2002. View Article : Google Scholar : PubMed/NCBI
32	Townsend DM and Tew KD: The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 22:7369–7375. 2003. View Article : Google Scholar : PubMed/NCBI
33	Huang MY, Huang ML, Chen MJ, Lu CY, Chen CF, Tsai PC, Chuang SC, Hou MF, Lin SR and Wang JY: Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics. 21:18–25. 2011. View Article : Google Scholar : PubMed/NCBI
34	Suh KW, Kim JH, Kim DY, Kim YB, Lee C and Choi S: Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol. 13:1379–1385. 2006. View Article : Google Scholar : PubMed/NCBI